Ardelyx (ARDX) Price & Analysis

Compare

1,738 Followers

ARDX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.21 - $7.18

Previous CloseN/A

Volume1.36M

Average Volume (3M)4.40M

Market Cap

$1.41B

Enterprise Value$908.71M

Total Cash (Recent Filing)$238.45M

Total Debt (Recent Filing)$206.64M

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Oct 30, 2025

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding240,982,830

10 Day Avg. Volume5,636,643

30 Day Avg. Volume4,398,465

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue2.35

Enterprise Value/Gross Profit2.76

Enterprise Value/Ebitda-28.30

Forecast

1Y Price Target

$10.75

Price Target Upside80.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

EarningsArdelyx delivered a top-line beat with total revenue driven by strong Ibsrela performance and solid Xphozah execution.

GuidanceManagement's confidence in Ibsrela's trajectory led to the raised 2025 guidance.

Product DifferentiationIbsrela remains the only non-secretagogue on the market, likely making it the preferred second-line agent and appealing to a large number of refractory patients.

Bears Say

Legal ChallengesCMS filed a motion to dismiss last year, which was granted by Judge Howell.

Medicare CoverageMedicare Part D no longer covers XPHOZAH and oral phosphate binders from January 1, 2025.

Revenue ExpectationsA small sequential retracement in overall Xphozah revenue is expected from the first quarter to the second quarter, with growth likely returning in the third quarter.

Ardelyx News

Ardelyx price target raised to $9 from $8 at Piper Sandler

Piper Sandler raised the firm’s price target on Ardelyx (ARDX) to $9 from $8 and keeps a Neutral...

10d ago

ARDX

Ardelyx price target raised to $14 from $13 at Wedbush

Wedbush raised the firm’s price target on Ardelyx (ARDX) to $14 from $13 and keeps an Outperform rating...

11d ago

ARDX

Ardelyx price target raised to $14 from $13 at Wedbush

Wedbush raised the firm’s price target on Ardelyx (ARDX) to $14 from $13 and keeps an Outperform rating...

11d ago

ARDX

Ardelyx price target raised to $12 from $11 at Raymond James

Raymond James raised the firm’s price target on Ardelyx (ARDX) to $12 from $11 and keeps an Outperform...

11d ago

ARDX

Ardelyx CFOO Justin Renz to depart, John Bishop named CTOO

Ardelyx (ARDX) announced changes to the executive leadership team. The company announced the appointment of Edward Conner to...

12d ago

ARDX

Ardelyx’s Strong Financial Performance and Strategic Positioning Drive Buy Rating and Increased Price Target

Ardelyx, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Roanna Ruiz from Leerink...

10d ago

ARDX

Ardelyx Inc. Faces Financial Uncertainty Amid Shifting Trade Policies

Ardelyx Inc (ARDX) has disclosed a new risk, in the Capital Markets category. Ardelyx Inc. faces significant risks...

11d ago

ARDX

Ardelyx Inc. Q2 2025 Earnings Call Highlights

Ardelyx Inc (($ARDX)) has held its Q2 earnings call. Read on for the main highlights of the call....

11d ago

ARDX

Ardelyx’s Strong Commercial Execution and Growth Prospects Drive Buy Rating

H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on ARDX stock, giving a Buy rating yesterday....

11d ago

ARDX

Ardelyx Reports Strong Q2 2025 Financial Performance

Ardelyx Inc ( ($ARDX) ) has released its Q2 earnings. Here is a breakdown of the information Ardelyx...

12d ago

ARDX

Ardelyx’s Strong Performance and Sales Outlook Justify Buy Rating

Analyst Joseph Thome from TD Cowen maintained a Buy rating on Ardelyx and keeping the price target at...

12d ago

ARDX

Ardelyx CFO Transition Announced Amid Strong Q2 Results

Ardelyx ( ($ARDX) ) just unveiled an announcement. On August 4, 2025, Ardelyx announced that its Chief Financial...

12d ago

ARDX

ARDX Earnings this Week: How Will it Perform?

Ardelyx Inc (ARDX) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding Q2...

15d ago

ARDX

Ardelyx’s Promising Growth Potential and Market Positioning: A Buy Recommendation

Analyst Julian Harrison of BTIG maintained a Buy rating on Ardelyx, retaining the price target of $14.00. Julian...

18d ago

ARDX

ARDX FAQ

What was Ardelyx Inc’s price range in the past 12 months?

Ardelyx Inc lowest stock price was $3.21 and its highest was $7.18 in the past 12 months.

What is Ardelyx Inc’s market cap?

Ardelyx Inc’s market cap is $1.41B.

When is Ardelyx Inc’s upcoming earnings report date?

Ardelyx Inc’s upcoming earnings report date is Oct 30, 2025 which is in 75 days.

How were Ardelyx Inc’s earnings last quarter?

Ardelyx Inc released its earnings results on Aug 04, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.132 by $0.052.

Is Ardelyx Inc overvalued?

According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ardelyx Inc pay dividends?

Ardelyx Inc does not currently pay dividends.

What is Ardelyx Inc’s EPS estimate?

Ardelyx Inc’s EPS estimate is -0.06.

How many shares outstanding does Ardelyx Inc have?

Ardelyx Inc has 240,982,830 shares outstanding.

What happened to Ardelyx Inc’s price movement after its last earnings report?

Ardelyx Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.132. Following the earnings report the stock price went up 16.856%.

Which hedge fund is a major shareholder of Ardelyx Inc?

Currently, no hedge funds are holding shares in ARDX

Ardelyx Stock Smart Score

Neutral

Fundamentals

Return on Equity

-39.36%

Trailing 12-Months

Asset Growth

35.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with gastrointestinal and renal diseases. The company operates primarily in the biotechnology sector and is known for its lead product, tenapanor, which is designed to treat conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx is committed to addressing unmet medical needs through its proprietary platform that targets the gut and kidneys.

Ardelyx (ARDX) Earnings & Revenues

Historic Earnings Reports

ARDX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial and product performance, particularly for IBSRELA, and strategic steps to strengthen the company's leadership and financial flexibility. However, challenges include the departure of a key executive and the impact of losing Medicare as a payer for XPHOZAH. The positive aspects of growth and strategic positioning slightly outweigh the challenges noted.View all ARDX earnings summaries

ARDX Stock 12 Month Forecast

Average Price Target

$10.75

▲(80.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","5.5":"$5.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.33,5.150769230769231,5.9715384615384615,6.792307692307693,7.613076923076923,8.433846153846154,9.254615384615384,10.075384615384616,10.896153846153847,11.716923076923077,12.537692307692309,13.358461538461539,14.17923076923077,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.33,4.823846153846154,5.317692307692308,5.811538461538461,6.305384615384615,6.799230769230769,7.293076923076923,7.786923076923077,8.28076923076923,8.774615384615384,9.268461538461539,9.762307692307692,10.256153846153847,{"y":10.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.33,4.42,4.51,4.6,4.69,4.78,4.87,4.96,5.05,5.14,5.23,5.32,5.41,{"y":5.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.57,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >